Discontinuation of TNF-alpha Inhibitors in Spondylarthritis Patients With Low Disease Activity, and Re-initiation of Therapy if Disease Flares.

Trial Profile

Discontinuation of TNF-alpha Inhibitors in Spondylarthritis Patients With Low Disease Activity, and Re-initiation of Therapy if Disease Flares.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary)
  • Indications Spondylarthritis
  • Focus Biomarker; Therapeutic Use
  • Acronyms SPARTA
  • Most Recent Events

    • 18 Aug 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 27 Mar 2012 Planned end date changed from 1 Dec 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov record.
    • 21 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top